1203 results about "Gastroenterology" patented technology

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention relates to a crystal form of a compound tigoran, a preparation method of the crystal form, a pharmaceutical composition containing the crystal form, and application of the crystal form in preparation of drugs for treating related diseases needing to control the pH value of gastric juice, such as gastroesophageal reflux disease and erosive esophagitis. The new crystal form DCVI of the compound tigorasone, provided by the invention, has an important value for the development of the medicine in the future.

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.

The invention discloses a prediction marker and a prediction method for acute upper respiratory infection susceptibility. The prediction marker and the prediction method are used for solving the problem that current acute upper respiratory infection susceptibility risk prediction is low in accuracy. The method comprises the following steps: firstly, providing a prediction marker for acute upper respiratory infection susceptibility, wherein the prediction marker is a prediction feature combination obtained by comprehensively considering human health state blood routine data and baseline blood transcriptome data and carrying out feature processing; secondly, providing a prediction method, and obtaining a to-be-detected blood sample; and performing blood analysis based on a to-be-detected blood sample, inputting the obtained blood routine sample and the gene expression sample into a susceptibility prediction model pre-trained based on a prediction marker for susceptibility risk judgment, and obtaining a susceptibility risk assessment result of acute upper respiratory infection of a human body corresponding to the to-be-detected blood sample in a future period of time, therefore, the acute upper respiratory infection susceptibility risk of the human body in a period of time in the future can be simply, quickly and accurately predicted.

This invention relates to the field of medical testing, specifically to a set of biomarkers, reagent kits, and their applications for diagnosing hypertension in children. This invention involves collecting tongue / intestinal samples from obese children with hypertension, obese children, and healthy individuals, performing metagenomic sequencing, and statistically analyzing the sequencing data using bioinformatics to identify disease-related tongue / intestinal flora. By integrating tongue / intestinal flora with disease information, a combination of flora biomarkers is obtained. A binary classification prediction model constructed using this combination can maximally detect hypertension in obese children.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention belongs to the technical field of biological medicine, and particularly relates to application of phenylalanine in evaluating Kawasaki disease and treating effect thereof and application of a phenylalanine inhibitor in treating Kawasaki disease. According to serum non-targeted metabonomics analysis and verification of KD children and IVIG treated KD children, phenylalanine is highly expressed in KD children, and phenylalanine is remarkably reduced after IVIG treatment of KD and tends to healthy children. The phenylalanine can be used as a serological marker for evaluating the Kawasaki disease treatment effect and diagnosing IVIG second-line treatment, and is high in specificity and sensitivity. After the phenylalanine inhibitor is administered to a KD model mouse, the content of phenylalanine in serum is remarkably reduced and is consistent with the trend in serum of the KD mouse treated by IVIG, myrica tongues are remarkably relieved, arterial dilatation is slowed down, and expression of inflammatory factors is reduced. The phenylalanine inhibitor has the effects of treating Kawasaki disease, improving myrica rubra tongue and slowing down arterial dilatation.

Provided herein are systems and methods for identifying a disease or disorder of a patient, identifying if a patient is likely to respond to a treatment for the disease or disorder, and / or predicting the clinical outcome of the disease or disorder of a patient. Systems and methods described herein may be directed to patients with different chronic conditions, inflammatory conditions, and / or autoimmune conditions. Systems and methods described herein may be directed to patients with a dermatological condition.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

The invention discloses a culture method of high-activity human urine-derived stem cells, which relates to the technical field of biological medicine, and is technically characterized by comprising the following steps: collecting urine samples of pregnant and lying-in women, coating a culture plate with gelatin, inducing adherence, performing passage amplification, performing immunofluorescence identification, performing function detection and other optimized conditions, and separating and culturing the stem cells. Compared with urine-derived stem cells of normal adults, the stem cells derived from pregnant women have stronger activity, higher dryness and faster multiplication capacity. The invention provides a novel and superior cell source for tissue engineering and regenerative medicine.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

Disclosed herein is a method of treating Idiopathic Pulmonary Fibrosis (IPF). The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 1650 mg to about 2500 mg.

The invention discloses a traditional Chinese medicine composition for treating gastroesophageal reflux disease and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from ginger processed pinellia, poria cocos, semen armeniacae amarae, thunberg fritillary bulb, radix paeoniae alba, pericarpium citri reticulatae, cuttlebone, cassia twig, moutan bark, concha arcae, honey-fried licorice root and the like. Clinical research results show that the qi-regulating and backflow-inhibiting decoction provided by the invention can remarkably improve clinical symptoms of patients with gastroesophageal reflux diseases, can remarkably improve psychological health feelings of the patients with gastroesophageal reflux diseases, and is high in treatment effective rate, low in recurrence rate and good in safety.

An apparatus and method for an oral nicotine dispensing system. The apparatus includes storing a plurality of a pods in a magazine within a body, receiving a fingerprint scan from a user via a fingerprint scanner coupled to the body, authenticating the fingerprint scan, de-activating a locking mechanism to allow access to at least a pod upon successful authentication of the fingerprint scan, and dispensing, using at least a drive mechanism, the at least a pod from the magazine through an opening of the body.

The invention relates to the field of biological medicines, in particular to application of an SR604 injection to preparation of a medicine for preventing and / or treating hemorrhagic diseases. The SR604 injection provided by the invention contains an SR604 antibody, and the injection dosage of the SR604 antibody in the SR604 injection is selected from 0.025 mg / kg to 0.8 mg / kg. The injection provided by the invention can be used for preventing and / or treating hemorrhagic diseases, the number of hemorrhagic events and the annual hemorrhagic rate of a patient are remarkably reduced by controlling the injection dosage and the injection frequency, and the injection has a relatively good treatment effect on hemophilia A, hemophilia B and congenital blood coagulation factor VII deficiency.

The invention discloses a metabonomics-based Citrus Huanglongbing marker combination and a screening method thereof, and relates to a method for screening biomarkers of an asymptomatic Citrus Huanglongbing sample, metabolite screened by the method is adopted to further construct a prediction model, and the prediction model is used for detecting Citrus Huanglongbing in asymptomatic leaves. The biomarker of the asymptomatic sample can be screened through the method, and the method is of great significance to improvement of diagnosis accuracy.

The invention discloses a Parabacteroides goldsteinii bacterium and application of a metabolite of the Parabacteroides goldsteinii bacterium in treatment of metabolism-related steatohepatitis and fibrosis related to the metabolism-related steatohepatitis. According to the application disclosed by the invention, firstly, through biological analysis, the fact that Parabacteroides goldsteinii and a metabolite 7-Sulfocholic acid of Parabacteroides goldsteinii are closely related to the progress of MASH related fibrosis is determined; furthermore, functional intervention is implemented in a CDAHFD model, the MASH and the related fibrosis process of the MASH can be remarkably inhibited by supplementing Parabacteroides goldsteinii or 7-Sulfocholic acid, the MASH and the related fibrosis process of the MASH can be relieved, liver fatty degeneration, inflammatory infiltration and collagen deposition can be relieved, and further conversion and application feasibility can be achieved.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention discloses application of roxburgh rose exosomes in preparation of products for preventing and treating acute alcoholic liver injury, relates to extraction of the roxburgh rose exosomes and new application of the roxburgh rose exosomes in prevention and treatment of the acute alcoholic liver injury, and belongs to the technical field of biology. The roxburgh rose exosome can also prevent and treat acute alcoholic liver injury. The particle size of the roxburgh rose exosome is 135.2 nm, the particle concentration is 1.3 * 10 < 11 > Particle / mL, and the total protein concentration is 2.12 mu g / mu L. A new thought is provided for research and development of drugs for preventing and treating acute alcoholic liver injury, the extraction method of the roxburgh rose exosome is simple, full development and utilization of food resources can be promoted, and a drug or a health care product for preventing and treating acute alcoholic liver injury is provided.

Disclosed herein are compositions and methods for the treatment of inflammatory bowel disease. According to some embodiments, the compositions and methods involve the use of a delayed-release capsule formulation containing a mesalamine layer, a hyaluronan layer, and at least one coating layer.

The invention belongs to the technical field of biological medicines, and relates to application of mannatide in preparation of a medicine for treating alcoholic gastric ulcer. The mannatide disclosed by the invention can be used for remarkably relieving gastric tissue hemorrhagic lesion and ulcer conditions of alcoholic gastric ulcer for the first time, and the mechanism comprises the following steps: reducing active oxygen generated by alcohol toxicity, and improving oxidative stress of a body by improving antioxidant enzyme activity of the gastric tissue; the inflammatory response of the organism is regulated by regulating and controlling an Akt / NF-kB pathway; a Bax-related apoptosis pathway is inhibited to protect gastric mucosa cells from alcohol-induced apoptosis, so that the integrity of gastric tissue mucosa is protected; the intestinal flora disorder caused by alcohol intake is regulated and controlled, and the acute alcoholic gastric ulcer is prevented by improving the intestinal flora composition of the alcoholic gastric ulcer. The application range of the mannatide is widened, and more solutions are provided for prevention or treatment of acute alcoholic gastric ulcer.

The disclosure provides for methods and compositions for treating respiratory obstructive diseases.

The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

This invention discloses a traditional Chinese medicine composition for treating male infertility due to liver stagnation and kidney deficiency, its preparation method, and its application, belonging to the fields of traditional Chinese medicine pharmaceutical technology and andrological reproductive health technology. The composition is formulated with Bupleurum chinense, Tribulus terrestris, Cynomorium songaricum, Cuscuta chinensis, Cornus officinalis, and Epimedium brevicornu in specific weight proportions, following the principles of soothing the liver and relieving stagnation, tonifying the kidney and replenishing essence, and unblocking the meridians to treat impotence. This invention employs an alcohol-water dual-phase fractional extraction process, and can be prepared into various dosage forms such as granules, capsules, and tablets. Pharmacological experiments have confirmed that the composition of this invention can increase sperm density and progressively motile sperm rate, improve penile tissue nitric oxide synthase (NOS) activity, regulate reproductive hormones, and reduce testicular oxidative damage; serum pharmacochemistry and metabolomics have clarified the active components entering the bloodstream and their pathways of action. This invention features a refined formulation, abundant medicinal resources, and simple preparation, making it suitable for large-scale production and clinical application in treating male infertility due to liver stagnation and kidney deficiency.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

The invention discloses application of a substance taking MANF as a target spot in preparation of a medicine for treating non-alcoholic steatohepatitis. The research finds that the expression of the MANF in liver tissues of a fatty liver patient and a non-alcoholic steatohepatitis model mouse is obviously up-regulated, and the weight, liver lipid accumulation and inflammatory infiltration of the NASH mouse can be obviously reduced by specifically knocking out the MANF by the macrophage, so that the MANF in the macrophage plays an important role in the NASH pathological process.

The invention relates to the technical field of medical instruments, in particular to a portable visual nasal gastrointestinal nutrition tube indwelling device which comprises an operation handle, an endoscope assembly, a guide wire and a shaping mechanism, and the endoscope assembly is connected to the operation handle, can be controlled by the operation handle and is used for checking conditions in the body of a patient; the endoscope assembly is sleeved with the nasal gastrointestinal nutrition tube when the nasal gastrointestinal nutrition tube is installed. The guide wire is inserted into the endoscope assembly and is used for supporting the endoscope assembly; the shaping mechanism is configured to enable the section shape of the nasal gastrointestinal nutrition tube with the curvature larger than a preset value to be recovered to be round and can also fix the shape of the nasal gastrointestinal nutrition tube with the curvature larger than the preset value. Therefore, on one hand, it can be guaranteed that the section of the nasal gastrointestinal nutrition tube is round and the blocking risk is avoided when the nasal gastrointestinal nutrition tube conveys nutrient solution or medicine, and on the other hand, elastic reset force generated at the bent position of the nasal gastrointestinal nutrition tube can be offset and the nasal gastrointestinal nutrition tube is prevented from continuously jacking mucous membranes and tissues in the human body.